{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:47:04Z","timestamp":1792705624377,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T00:00:00Z","timestamp":1606953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T00:00:00Z","timestamp":1606953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Saroglitazar, a dual peroxisome proliferator activated receptor \u03b1\/\u03b3 agonist, approved for diabetic dyslipidemia (DD), is potential therapeutic option for non-alcoholic fatty liver disease (NAFLD). This prospective, observational, real-world study aimed to determine efficacy and safety of Saroglitazar in patients with NAFLD and DD. We included patients with DD and NAFLD who received Saroglitazar 4\u00a0mg once daily for 24\u00a0weeks. Blood investigations, liver stiffness measurement (LSM) and controlled attenuation parameter (CAP) (FibroScan) were compared at baseline and 24\u00a0weeks. Of 163 patients screened, 107 were included, and 101 completed 24\u00a0weeks treatment (mean age 50.4\u2009\u00b1\u200912.3\u00a0years, 78.5% males, mean body mass index 28.8\u2009\u00b1\u20094.2). After 24\u00a0weeks, alanine transaminase (ALT) reduced significantly from 94 (47\u2013122) to 39 (31\u201349) (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) and aspartate aminotransferase (AST) (U\/L) from 89 (43\u2013114) to 37 (30\u201347) (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) and LSM (kPa) from 8.4 (7.1\u20139.3) to 7.5 (6.4\u20138.4) (<jats:italic>p<\/jats:italic>\u2009=\u20090.0261). CAP, glycated hemoglobin and lipid parameters also improved significantly. On linear regression, there was significant association between percent change in ALT and AST with TG reduction after treatment (<jats:italic>p<\/jats:italic>\u2009=\u20090.024 and 0.037 respectively).We conclude that Saroglitazar leads to significant improvement in transaminases, LSM, and CAP in NAFLD patients with DD.<\/jats:p>","DOI":"10.1038\/s41598-020-78342-x","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T11:02:35Z","timestamp":1606993355000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study"],"prefix":"10.1038","volume":"10","author":[{"given":"Omesh","family":"Goyal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahil","family":"Nohria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prerna","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaskirat","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarit","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajit","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajoo Singh","family":"Chhina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,3]]},"reference":[{"key":"78342_CR1","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jceh.2015.02.006","volume":"5","author":"A Duseja","year":"2015","unstructured":"Duseja, A. et al. Non-alcoholic fatty liver disease and metabolic syndrome-position paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology. J. Clin. Exp. Hepatol. 5, 51\u201368 (2015).","journal-title":"J. Clin. Exp. Hepatol."},{"key":"78342_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2337\/diaclin.24.1.27","volume":"24","author":"MP Solano","year":"2006","unstructured":"Solano, M. P. & Goldberg, R. B. Lipid management in type 2 diabetes. Clin. Diabetes 24, 27\u201332 (2006).","journal-title":"Clin. Diabetes"},{"key":"78342_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/cld.708","volume":"11","author":"N Alkhouri","year":"2018","unstructured":"Alkhouri, N. & Scott, A. An update on the pharmacological treatment of non-alcoholic fatty liver disease: beyond lifestyle modifications. Clin. Liver Dis. 11, 82\u201386 (2018).","journal-title":"Clin. Liver Dis."},{"key":"78342_CR4","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","volume":"65","author":"PS Dulai","year":"2017","unstructured":"Dulai, P. S. et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 65, 1557\u20131565 (2017).","journal-title":"Hepatology"},{"key":"78342_CR5","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.jceh.2019.06.004","volume":"9","author":"NS Choudhary","year":"2019","unstructured":"Choudhary, N. S., Kumar, N. & Duseja, A. Peroxisome proliferator-activated receptors and their agonists in nonalcoholic fatty liver disease. J. Clin. Exp. Hepatol. 9, 731\u2013739 (2019).","journal-title":"J. Clin. Exp. Hepatol."},{"key":"78342_CR6","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/liv.13634","volume":"38","author":"MR Jain","year":"2018","unstructured":"Jain, M. R. et al. Dual PPAR\u03b1\/\u03b3 agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models. Liver Int. 38, 1084\u20131094 (2018).","journal-title":"Liver Int."},{"key":"78342_CR7","doi-asserted-by":"publisher","first-page":"9330","DOI":"10.1038\/s41598-020-66458-z","volume":"10","author":"DP Kumar","year":"2020","unstructured":"Kumar, D. P. et al. The PPAR \u03b1\/\u03b3 agonist saroglitazar improves insulin resistance and steatohepatitis in a diet induced animal model of nonalcoholic fatty liver disease. Sci. Rep. 10, 9330 (2020).","journal-title":"Sci. Rep."},{"key":"78342_CR8","doi-asserted-by":"publisher","first-page":"S326","DOI":"10.1007\/s12072-020-10016-2","volume":"14","author":"SK Sarin","year":"2020","unstructured":"Sarin, S. K. et al. A prospective, multi-centre, double-blind, randomized trial of Saroglitazar 4 mg compared to placebo in patients with nonalcoholic steatohepatitis. Hepatol. Int. 14, S326 (2020).","journal-title":"Hepatol. Int."},{"key":"78342_CR9","doi-asserted-by":"publisher","first-page":"1484A","DOI":"10.1002\/hep.30783","volume":"70","author":"S Gawrieh","year":"2019","unstructured":"Gawrieh, S. et al. A phase 2, prospective, multicentre, double-blind, randomized study of Saroglitazar magnesium 1 mg, 2 mg or 4 mg versus placebo in patients with nonalcoholic fatty liver disease and\/or nonalcoholic steatohepatitis (EVIDENCES IV). Hepatology 70, 1484A (2019).","journal-title":"Hepatology"},{"key":"78342_CR10","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3350\/cmh.2019.0001n","volume":"26","author":"X Zhang","year":"2020","unstructured":"Zhang, X., Wong, G. L. & Wong, V. W. Application of transient elastography in nonalcoholic fatty liver disease. Clin. Mol. Hepatol. 26, 128\u2013141 (2020).","journal-title":"Clin. Mol. Hepatol."},{"key":"78342_CR11","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","volume":"156","author":"PJ Eddowes","year":"2019","unstructured":"Eddowes, P. J. et al. Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 156, 1717\u20131730 (2019).","journal-title":"Gastroenterology"},{"key":"78342_CR12","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/hep.23312","volume":"51","author":"VW Wong","year":"2010","unstructured":"Wong, V. W. et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 51, 454\u2013462 (2010).","journal-title":"Hepatology"},{"key":"78342_CR13","doi-asserted-by":"publisher","first-page":"4959","DOI":"10.3748\/wjg.v25.i33.4959","volume":"25","author":"JI Lee","year":"2019","unstructured":"Lee, J. I., Lee, H. W. & Lee, K. S. Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis. World J. Gastroenterol. 25, 4959\u20134969 (2019).","journal-title":"World J. Gastroenterol."},{"key":"78342_CR14","first-page":"281","volume":"28","author":"P Pathik","year":"2015","unstructured":"Pathik, P. et al. Fibroscan versus simple noninvasive screening tools in predicting fibrosis in high-risk nonalcoholic fatty liver disease patients from Western India. Ann. Gastroenterol. 28, 281\u2013286 (2015).","journal-title":"Ann. Gastroenterol."},{"key":"78342_CR15","doi-asserted-by":"publisher","first-page":"e0182784","DOI":"10.1371\/journal.pone.0182784","volume":"12","author":"BG Jun","year":"2017","unstructured":"Jun, B. G. et al. A prospective comparative assessment of the accuracy of the FibroScan in evaluating liver steatosis. PLoS ONE 12, e0182784 (2017).","journal-title":"PLoS ONE"},{"key":"78342_CR16","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","volume":"150","author":"V Ratziu","year":"2016","unstructured":"Ratziu, V. et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-\u03b1 and \u03b4 induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 150, 1147\u20131159 (2016).","journal-title":"Gastroenterology"},{"key":"78342_CR17","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1097\/MEG.0000000000001369","volume":"31","author":"A Anushiravani","year":"2019","unstructured":"Anushiravani, A., Haddadi, N., Pourfarmanbar, M. & Mohammadkarimi, V. Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial. Eur. J. Gastroenterol. Hepatol. 31, 613\u2013617 (2019).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"78342_CR18","doi-asserted-by":"publisher","first-page":"264","DOI":"10.14218\/JCTH.2017.00056","volume":"6","author":"JJ Connolly","year":"2018","unstructured":"Connolly, J. J., Ooka, K. & Lim, J. K. Future pharmacotherapy for non-alcoholic steatohepatitis (NASH): review of phase 2 and 3 trials. J. Clin. Transl. Hepatol. 6, 264\u2013275 (2018).","journal-title":"J. Clin. Transl. Hepatol."},{"key":"78342_CR19","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","volume":"394","author":"ZM Younossi","year":"2019","unstructured":"Younossi, Z. M. et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 394, 2184\u20132196 (2019).","journal-title":"Lancet"},{"key":"78342_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ihj.2015.02.007","volume":"67","author":"SR Shetty","year":"2015","unstructured":"Shetty, S. R., Kumar, S., Mathur, R. P., Sharma, K. H. & Jaiswal, A. D. Observational study to evaluate the safety and efficacy of Saroglitazar in Indian diabetic dyslipidaemia patients. Indian Heart J. 67, 23\u201326 (2015).","journal-title":"Indian Heart J."},{"key":"78342_CR21","doi-asserted-by":"publisher","first-page":"819","DOI":"10.35248\/2155-6156.19.10.819","volume":"10","author":"U Kaul","year":"2019","unstructured":"Kaul, U. et al. A prospective, multicentre, single arm clinical study to evaluate the effect of Saroglitazar on non high-density lipoprotein cholesterol in patients with diabetic dyslipidaemia inadequately controlled with diet, exercise, and statin\u2014the GLIDDER Study. J. Diabetes Metab. 10, 819 (2019).","journal-title":"J. Diabetes Metab."},{"key":"78342_CR22","first-page":"000180","volume":"3","author":"S Chatterjee","year":"2018","unstructured":"Chatterjee, S., Majumder, A., Ray, S. & Bhattacharjee, K. Observational study of Saroglitazar on metabolic parameters in Indian patients with diabetic dyslipidaemia\u2014a fifty-eight weeks of clinical experience. Diabetes Obes. Int. 3, 000180 (2018).","journal-title":"Diabetes Obes. Int."},{"key":"78342_CR23","doi-asserted-by":"publisher","first-page":"7706","DOI":"10.1038\/srep07706","volume":"5","author":"S Chatterjee","year":"2015","unstructured":"Chatterjee, S., Majumder, A. & Ray, S. Observational study of effects of saroglitazar on glycaemic and lipid parameters on Indian patients with type 2 diabetes. Sci. Rep. 5, 7706 (2015).","journal-title":"Sci. Rep."},{"key":"78342_CR24","doi-asserted-by":"publisher","first-page":"19017","DOI":"10.1038\/s41598-019-55466-3","volume":"9","author":"N Jain","year":"2019","unstructured":"Jain, N. et al. Effect of a dual PPAR \u03b1\/\u03b3 agonist on insulin sensitivity in patients of type 2 diabetes with hypertriglyceridemia\u2014randomized double-blind placebo-controlled trial. Sci. Rep. 9, 19017 (2019).","journal-title":"Sci. Rep."},{"key":"78342_CR25","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.14309\/ajg.0000000000000388","volume":"114","author":"S Gawrieh","year":"2019","unstructured":"Gawrieh, S. et al. NASH clinical research network. Histologic findings of advanced fibrosis and cirrhosis in patients with nonalcoholic fatty liver disease who have normal aminotransferase levels. Am. J. Gastroenterol. 114, 1626\u20131635 (2019).","journal-title":"Am. J. Gastroenterol."},{"key":"78342_CR26","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1530-891X(20)44880-3","volume":"22","author":"S Joshi","year":"2016","unstructured":"Joshi, S. et al. Saroglitazar in non-alcoholic fatty liver disease. Endocrine Pract. 22, 331 (2016).","journal-title":"Endocrine Pract."},{"key":"78342_CR27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.soard.2017.09.005","volume":"14","author":"H Garg","year":"2018","unstructured":"Garg, H. et al. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients. Surg. Obes. Relat. Dis. 14, 81\u201391 (2018).","journal-title":"Surg. Obes. Relat. Dis."},{"key":"78342_CR28","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1007\/s11695-014-1235-9","volume":"24","author":"S Naveau","year":"2014","unstructured":"Naveau, S. et al. The diagnostic accuracy of transient elastography for the diagnosis of liver fibrosis in bariatric surgery candidates with suspected NAFLD. Obes. Surg. 24, 1693\u20131701 (2014).","journal-title":"Obes. Surg."},{"key":"78342_CR29","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1002\/hep.29639","volume":"67","author":"C Caussy","year":"2018","unstructured":"Caussy, C. et al. Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis. Hepatology 67, 1348\u20131359 (2018).","journal-title":"Hepatology"},{"key":"78342_CR30","doi-asserted-by":"publisher","first-page":"7236","DOI":"10.3748\/wjg.v22.i32.7236","volume":"22","author":"I Mikolasevic","year":"2016","unstructured":"Mikolasevic, I. et al. Transient elastography (FibroScan) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease\u2014Where do we stand?. World J. Gastroenterol. 22, 7236\u20137251 (2016).","journal-title":"World J. Gastroenterol."},{"key":"78342_CR31","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1177\/1932296813518680","volume":"8","author":"V Pai","year":"2014","unstructured":"Pai, V. et al. A multicentre, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared to pioglitazone 45 mg in diabetic dyslipidaemia (PRESS V). J. Diabetes Sci. Technol. 8, 132\u2013141 (2014).","journal-title":"J. Diabetes Sci. Technol."},{"key":"78342_CR32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1089\/dia.2013.0253","volume":"16","author":"RH Jani","year":"2014","unstructured":"Jani, R. H. et al. A multicentre, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI). Diabetes Technol. Ther. 16, 63\u201371 (2014).","journal-title":"Diabetes Technol. Ther."},{"key":"78342_CR33","doi-asserted-by":"publisher","first-page":"BSR20193996","DOI":"10.1042\/BSR20193996","volume":"40","author":"C Chen","year":"2020","unstructured":"Chen, C. et al. HbA1c may contribute to the development of non-alcoholic fatty liver disease even at normal-range levels. Biosci. Rep. 40, BSR20193996 (2020).","journal-title":"Biosci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78342-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78342-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78342-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:27:29Z","timestamp":1670372849000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78342-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,3]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["78342"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-78342-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,3]]},"assertion":[{"value":"12 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21117"}}